We postulated that, besides pre-NAT biomarkers, characterisation of residual tumours in non-responder patients and comparison with their pre-treatment counterparts could contribute to better knowledge of the mechanisms involved in NAT resistance and help in the prediction and prognosis of BC. The gene discussed is BRD2; the disease is breast cancer.